Allergy Therapeutics (LSE:AGY) Net Issuance of Debt : £34.31 Mil (TTM As of Jun. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Allergy Therapeutics Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Allergy Therapeutics's net issuance of debt for the six months ended in Jun. 2024 was £60.64 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Jun. 2024 was £34.31 Mil.

Allergy Therapeutics Net Issuance of Debt Historical Data

The historical data trend for Allergy Therapeutics's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Net Issuance of Debt Chart

Allergy Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Net Issuance of Debt

Get a 7-Day Free Trial

1.23

-0.13

-0.96

25.75

34.31

Allergy Therapeutics Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Net Issuance of Debt	Get a 7-Day Free Trial															-0.49	-0.53	26.28	-26.33	60.64

Allergy Therapeutics Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £34.31 Mil.

Allergy Therapeutics Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Allergy Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allergy Therapeutics PLC (LSE:AGY) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

AGYTF:USA HHU:Germany

Address

Dominion Way, Worthing, West Sussex, GBR, BN14 8SA

Website

https://www.allergytherapeutics.com

Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany, Austria, Netherlands, and Switzerland.

Allergy Therapeutics Headlines

No Headlines